Guardian Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Guardian Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-18,500	Closed	-$449K	–	54
2018 Q2	$449K	Buy	18,500 +2,050	+12%	+$41.8K	0.43%	53
2018 Q1	$282K	Buy	16,450 +250	+2%	+$4.88K	0.3%	51
2017 Q4	$307K	Sell	16,200 -1,500	-8%	-$22.6K	0.32%	51
2017 Q3	$311K	Buy	17,700 +3,750	+27%	+$84.4K	0.34%	53
2017 Q2	$463K	Buy	13,950 +500	+4%	+$15.5K	0.51%	50
2017 Q1	$432K	Buy	13,450 +525	+4%	+$17.9K	0.47%	50
2016 Q4	$468K	Buy	12,925 +510	+4%	+$20.4K	0.54%	48
2016 Q3	$623K	Hold	12,415	–	–	0.69%	45
2016 Q2	$623K	Sell	12,415 -1,050	-8%	-$55.9K	0.69%	45
2016 Q1	$721K	Sell	13,465 -900	-6%	-$52.8K	0.83%	42
2015 Q4	$942K	Hold	14,365	–	–	1.01%	38
2015 Q3	$840K	Sell	14,365 -635	-4%	-$41.2K	0.93%	43
2015 Q2	$914K	Hold	15,000	–	–	1.02%	40
2015 Q1	$929K	Sell	15,000 -7,000	-32%	-$407K	1.03%	40
2014 Q4	$1.26M	Buy	+22,000	New	+$1.23M	1.33%	34

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Guardian Investment Management's TEVA Position: Q3 2018 in Review

Guardian Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2018, closing a stake of 18,500 shares — an estimated $449K sold.

Guardian Investment Management first reported a position in TEVA in Q4 2014 and held it in 15 quarters. The position peaked at $1.26M in Q4 2014. 557 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

Guardian Investment Management reported no remaining Teva Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Guardian Investment Management sold 18,500 Teva Pharmaceuticals shares in Q3 2018, an estimated $449K.
Guardian Investment Management first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 15 quarters.
Guardian Investment Management's Teva Pharmaceuticals position peaked at $1.26M in Q4 2014.
557 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on Guardian Investment Management's 13F filing for Q3 2018, filed 19 Oct 2018.